Intergroup Ewing's sarcoma study. Local control related to radiation dose, volume, and site of primary lesion in Ewing's sarcoma

Razek, Aly; Pérez, Carlos A.; Tefft, Melvin; Nesbit, Mark E.; Vietti, Teresa J.; Burgert, E. Omer; Kissane, John M.; Pritchard, Douglas J.; Gehan, Edmund A.

doi:10.1002/1097-0142(19800801)46:3<516::aid-cncr2820460316>3.0.co;2-k

Cited by 108 publications

(58 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…13) Long-term survival can be expected in patients with Ewing's sarcoma when the tumor is radically excised, followed by radiation and chemotherapy. 24,25) This appears to be true for cranial Ewing's sarcoma as well. Distinction of primary from metastatic cranial Ewing's sarcoma is definitely important as the primary tumor can often be successfully managed by intensive therapy, including radical excision.…”

Section: Discussionmentioning

confidence: 99%

Primary Ewing's Sarcoma of the Occipital Bone. Case Report.

Erol

Özveren

Özercan

et al. 2001

Neurol. Med. Chir.(Tokyo)

View full text Add to dashboard Cite

A 17-year-old female presented with a very rare case of primary Ewing's sarcoma of the skull involving the occipitotemporal region. Systemic examination found no evidence of metastasis. The tumor was surgically removed, and the patient underwent radiotherapy and chemotherapy. Fourteen months after surgery there has been no recurrence of the tumor. Cranial primary Ewing's tumor has a good prognosis after radical surgery and adjuvant therapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Primary Ewing's Sarcoma of the Occipital Bone. Case Report.

Erol

Özveren

Özercan

et al. 2001

Neurol. Med. Chir.(Tokyo)

View full text Add to dashboard Cite

show abstract

“…[11][12][13][14][15][16] Similar to the ES79 protocol, surgery was seldom used, and RT alone was used in [75% of the patients. 11,12,15,[17][18][19] The ES87 protocol built on the evidence indicating the efficacy of IE, 20 and incorporated this pair into a VACD backbone. 7 However, using similar local control approaches to the ES79 protocol, the addition of IE in the ES87 protocol did not appear to improve the outcomes.…”

Section: Advances In the Treatment Of Esftmentioning

confidence: 99%

Analysis of prognostic factors in ewing sarcoma family of tumors

Rodríguez‐Galindo

Liu

Krasin

et al. 2007

Cancer

211

111

View full text Add to dashboard Cite

BACKGROUND.Advances in systemic and local therapies have improved outcomes for patients with the Ewing sarcoma family of tumors (ESFT). As new treatments are developed, a critical review of data from past treatment eras is needed to identify clinically relevant risk groups.METHODS.The authors reviewed the records of 220 patients with ESFT who were treated on protocols at St. Jude Children's Research Hospital from 1979 to 2004. Two treatment eras were defined. Factors predictive of outcome were analyzed to identify distinct risk groups.RESULTS.The median age at diagnosis was 13.7 years (range, 1.1–25.2 years). Metastatic disease was associated with tumors measuring >8 cm (P = .002) and axial location (P = .014). The 5‐year overall survival (OS) estimate (63.5% ± 3.5%) did not appear to differ by protocol. Tumor stage and size were found to be the only independent predictors of outcome. Treatment era and type of local control therapy were found to influence the outcome of patients with localized disease. Four risk groups were defined: favorable risk (age <14 years with localized, nonpelvic tumors), intermediate risk (localized, age ≥14 years, or pelvic tumors), unfavorable‐pulmonary (isolated lung metastases), and unfavorable‐extrapulmonary (extrapulmonary metastases). The 5‐year OS estimates for these groups were 88.1% ± 4.4%, 64.9% ± 5.2%, 53.8% ± 9.4%, and 27.2% ± 7.3%, respectively (P < .001). The incidence of therapy‐related leukemia was significantly higher during the second treatment era, when more intensified regimens were used (6.1% ± 2.7% vs 0% ± 0%; P = .005).CONCLUSIONS.Risk stratification schemes such as this should be used to prospectively evaluate novel risk‐based therapies. Studies of biologic pathways may help to refine this model. Cancer 2007. © 2007 American Cancer Society.

show abstract

“…The treatment of ES/PNET has improved dramatically. The five year survival rate was less than 10% in the past but has now improved to 75% with the use of multimodal therapy which includes surgery, high dose irradiation and multidrug chemotherapy [15]. The chemotherapy regimens that have been used include VAC( Vincristine, Actinomycin D, cyclophosphamide), VACA (VAC+ Adriamycin) and VAC alternating IE (Ifosfamide and etoposide) [16].…”

Section: Discussionmentioning

confidence: 90%